[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou Institute of Respiratory Disease\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":293},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,65,101,123,144,177,196,224,244,270],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100554318","phase-2-maintenance-lurbinectedin-in-combination-with-serplulimab-for-patients-with-es-sclc-100554318",false,"NCT06497530","Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC","An Exploratory Study of Maintenance Lurbinectedin in Combination With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria for the Induction Phase:\n\n* Fully informed about the study and voluntarily signed a written informed consent form, and able to comply with the requirements and restrictions listed in the informed consent form;\n* Male or female with age ≥ 18 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;\n* Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment for ES-SCLC;\n* At least one measurable lesion (according to RECIST 1.1 criteria);\n* Having adequate bone marrow, hepatic, renal and metabolic function, meaning the functional level of the organs meets the following requirements:\n* Platelet count (PLT) ≥ 100×10\\^9\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL; Absolute neutrophil count (ANC) ≥ 2.0×10\\^9\u002FL;\n* Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0×upper limit of normal (ULN);\n* Alkaline phosphatase (ALP) ≤ 5×ULN;\n* Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;\n* Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n* Creatine phosphokinase (CPK) ≤ 2.5×ULN;\n* Albumin ≥ 3.0 g\u002FdL.\n* Women of childbearing potential(WOCBP) must have a negative serum pregnancy test before enrollment. WOCBP must use effective contraceptive measure during the trial drug treatment and for 6 months after the last administration. Male patients (with partners of WOCBP) must use effective contraceptive measure during the trial drug treatment and for 4 months after the last administration;\n* Human immunodeficiency virus (HIV)-negative, with no active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n\nExclusion Criteria for the Induction Phase:\n\n* Have a history of central nervous system (CNS) metastasis or related history;\n* Have a history of active autoimmune disease or immunodeficiency, or related history;\n* Have a history of malignancies other than SCLC within 5 years before enrollment;\n* Previous treatment with immune checkpoint inhibitors or lurbinectedin;\n* Have a history of idiopathic pulmonary fibrosis or pneumonia, or active pneumonia detected in CT screening;\n* Treatment with any other investigational product within 28 days before enrollment.\n\nInclusion Criteria for the Maintenance Phase:\n\n* Have a continuous response or stable disease according to RECIST 1.1 criteria after 4 cycles of induction therapy;\n* Toxicity from the induction therapy phase has recovered to ≤ Grade 1;\n* Have sufficient bone marrow and organ function.\n\nExclusion Criteria for the Maintenance Phase:\n\n* Have a history of central nervous system (CNS) metastasis or related history;\n* Has received chest consolidation radiotherapy;\n* Severe infection within 2 weeks before enrollment.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a single-arm, open-lable exploratory study of Lurbinectedin in combination with Serplulimab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and Serplulimab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and Serplulimab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will receive lurbinectedin plus Serplulimab in the maintenance phase.",[26],"Extensive-Stage Small Cell Lung Cancer","RECRUITING","2026-06-04",{"date":30,"type":31},"2026-06-08","ACTUAL",{"date":33,"type":31},"2024-12-01",{"date":35,"type":20},"2026-12",{"name":37,"class":38},"Guangzhou Institute of Respiratory Disease","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100637654","study-on-the-mechanism-of-adc-drug-evaluation-based-on-immune-co-culture-of-lung-cancer-organoids-100637654","NCT07610616","Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Availability of patient-derived organoids (PDOs) with matched autologous tumor-infiltrating lymphocytes (TILs) or peripheral blood mononuclear cells (PBMCs) from non-small cell lung cancer (NSCLC) cases.\n* Patients currently undergoing or scheduled to receive Trastuzumab deruxtecan (T-DXd) therapy who meet clinical eligibility criteria.\n* Provision of written informed consent.\n* PDOs exhibiting strong positive HER2 and TROP2 expression by immunohistochemistry (IHC) assigned to the experimental group.\n* PDOs exhibiting weak positive HER2 and TROP2 expression by IHC assigned to the negative control group.\n\nExclusion Criteria:\n\n* PDOs derived from patients with pathologically confirmed small cell lung cancer (SCLC).\n* Unavailability of matched autologous PDOs, TILs, or PBMCs.\n* Presence of any contraindications to T-DXd treatment.\n* Presence of other serious comorbidities resulting in an estimated survival of \\\u003C3 months.\n* Pregnant or breastfeeding women.","100 Years",{"count":48,"type":20},10,"OBSERVATIONAL","A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures. Focusing on HER2-positive and TROP2-positive non-small cell lung cancer (NSCLC) cases, ADC candidates were screened for in vitro activity based on organoid-immune interaction models.\n\nKey assessments included:\n\nTumor killing efficiency, assessed by dose-response relationships; Drug internalization (cellular uptake), as a measure of penetration into cancer cells; Antibody-dependent cellular cytotoxicity (ADCC) and bystander effect, with negative control targets employed to delineate specificity; Single-cell RNA sequencing, to profile transcriptional alterations at single-cell resolution.\n\nData demonstrated distinct ADC responses correlating with target expression and immune microenvironment features. The integrated approach provided cell-based evidence of ADC potency and revealed mechanistic insights-including immune-mediated cytotoxicity pathways and intracellular trafficking-supporting the rational design of clinical trials. These findings established a foundation for precision immunotherapy strategies and offered a mechanistic rationale for patient selection in HER2\u002FTROP2-positive lung cancer.",[52],"HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer",[54,55,56],"Non-Small Cell Lung Cancer","HER2 Positive Non-Small Cell Lung Cancer","TROP2 Positive Non-Small Cell Lung Cancer","2026-05-25",{"date":59,"type":31},"2026-05-28",{"date":61,"type":31},"2025-12-28",{"date":63,"type":20},"2027-10-01",{"name":37,"class":38},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":39},"100635607","nutritional--usual-corticosteroids-randomized-trial-for-immune-related-pneumonia---therapeutic-utilization-evaluation-100635607","NCT07554885","Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation","A Single-Center, Open-Label, Randomized Controlled Clinical Trial Comparing Nutritional Therapy (Spirulina-Bifidobacterium Capsules, Fish Oil-Grape Seed-Blueberry Soft Capsules, and Ganoderma Spore Oil) Combined With Standard Glucocorticoid Regimen Versus Standard Glucocorticoid Regimen Alone in the Treatment of Immune Checkpoint Inhibitor-Related Pneumonitis","Inclusion Criteria:\n\n1. Voluntary participation with full understanding of the study and signed informed consent form.\n2. Age 18 to 75 years (inclusive) on the day of informed consent signing.\n3. Histologically or cytologically confirmed malignancy.\n4. Received at least one cycle of immune checkpoint inhibitor therapy.\n5. Grade 3-4 immune-related pneumonitis (per CTCAE v5.0 and radiologic grading).\n6. ECOG performance status 0-2, with expected survival of more than 3 months.\n7. Adequate organ function based on laboratory results (without transfusion, apheresis, erythropoietin, or granulocyte colony-stimulating factor support within 14 days before the first dose). Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose.\n\nExclusion Criteria:\n\n1. Severe cardiac, cerebrovascular, renal, hematologic, or other serious systemic disease, including: NYHA Class III-IV heart failure; acute myocardial infarction or unstable angina within 6 months; severe post-stroke functional impairment (mRS greater than or equal to 3); progressive neurodegenerative disease; Child-Pugh Class B or C liver disease or acute liver failure; CKD stage 4-5 (eGFR less than 30 mL\u002Fmin\u002F1.73 m2) or requiring dialysis; absolute neutrophil count less than 1.5 x 10\\^9\u002FL, platelet count less than 50 x 10\\^9\u002FL, or Grade 3 or higher anemia (Hb less than 8 g\u002FdL).\n2. Severe allergic constitution or contraindications to the study treatment.\n3. Significant psychiatric or psychological disorder, or doubts about the treatment plan.\n4. Investigator judgment that the patient is unsuitable for the trial (e.g., poor follow-up adherence, refusal of supportive care).\n5. Use of anti-tumor traditional Chinese medicine within 14 days before first dose.\n6. History of or active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).\n7. Severe acute or chronic infection.\n8. Known alcohol or drug abuse history.\n9. Pregnancy or breastfeeding.\n10. Use of antibiotics, probiotic food, or microecological preparations within 2 weeks before enrollment.\n11. Prior treatment-related lung injury: (a) targeted-therapy-related pulmonary toxicity (prior EGFR-TKI, ALK inhibitor, VEGF inhibitor, or antibody-drug conjugate causing interstitial lung disease or pneumonitis that has not fully resolved, with radiologic fibrosis or persistent functional impairment); (b) thoracic radiation-related lung injury (radiation pneumonitis or radiation fibrosis with irreversible CT findings).\n12. Use of another investigational drug within 28 days before first dose that, per investigator judgment, would interfere with evaluation of study treatment.\n13. Gastrointestinal disorder precluding oral administration.","75 Years",{"count":74,"type":20},60,[76],"NA","This is a prospective, single-center, open-label, randomized controlled clinical trial evaluating whether the addition of a nutritional therapy regimen (Spirulina-Bifidobacterium capsules, fish oil-grape seed-blueberry soft capsules, and Ganoderma spore oil) to standard glucocorticoid therapy improves outcomes in patients with Grade 3-4 immune checkpoint inhibitor-related pneumonitis (CIP), compared with standard glucocorticoid therapy alone.\n\nA total of 60 patients with malignancies who develop Grade 3-4 CIP (per CTCAE v5.0) after at least one cycle of immune checkpoint inhibitor therapy will be randomized 1:1 to the experimental or control arm. The primary endpoints are time to pneumonitis downgrading and the proportion of patients achieving downgrading at 3 months.",[79,80,81],"Immune Checkpoint Inhibitor-Related Pneumonitis","Drug-Related Side Effects and Adverse Reactions","Neoplasms",[83,84,85,86,87,88,89,90,91],"Immune checkpoint inhibitor","Pneumonitis","Immune-related adverse events","Glucocorticoids","Spirulina","Bifidobacterium","Grape seed proanthocyanidin","Ganoderma spore oil","Antioxidant","NOT_YET_RECRUITING","2026-05-21",{"date":95,"type":31},"2026-05-26",{"date":97,"type":20},"2026-04",{"date":99,"type":20},"2029-10",{"name":37,"class":38},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100600026","phase-2-nano-crystalline-megestrol-acetate-for-anorexia-cachexia-syndrome-in-advanced-lung-cancer-100600026","NCT07092137","Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer","Nano-crystalline Megestrol Acetate for Anorexia-Cachexia in Advanced Lung Cancer: A Randomized, Double-Blind, Multicenter Study","Inclusion Criteria:\n\nPatients must meet all the following criteria to be eligible for study enrollment:\n\n1. Inclusion criteria for advanced lung cancer:\n\n   1. Patients with histologically or cytologically confirmed locally advanced (Stage ⅢC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that cannot be completely resected surgically or treated with radical chemoradiotherapy, according to the 8th edition of the TNM staging classification for lung cancer by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification.\n   2. Patients with histologically or cytologically confirmed small cell lung cancer (SCLC) and diagnosed as extensive-stage SCLC based on the 8th edition of AJCC staging or the Veterans Administration Lung Group (VALG) criteria (excluding mixed small cell lung cancer).\n   3. Subjects who have not received prior systemic chemotherapy for metastatic disease. Subjects who received adjuvant\u002Fneoadjuvant chemotherapy or radical concurrent\u002Fsequential chemoradiotherapy with curative intent for non-metastatic disease are eligible if disease progression occurs \\>6 months after the end of the last treatment.\n   4. At least one measurable tumor lesion according to RECIST v1.1.\n2. Criteria for pre-cachexia or cachexia stage:\n\n   1. Pre-cachexia diagnostic criteria (all three must be met):\n\n      * Unintentional weight loss ≤5% in the past 6 months;\n\n        ② Systemic inflammation (CRP \\>5 mg\u002FL);\n\n        ③ Decreased appetite (FAACT-A\u002FCS 12 score ≤37).\n   2. Fearon diagnostic criteria for cachexia stage (any one of the following combined with decreased appetite \\[FAACT-A\u002FCS 12 score ≤37\\] or systemic inflammation \\[CRP \\>5 mg\u002FL\\]):\n\n      * Unintentional weight loss \\>5% in the past 6 months; ② Weight loss \\>2% when BMI \\\u003C18.5 kg\u002Fm².\n3. General inclusion requirements:\n\n   1. Good compliance and signed informed consent form.\n   2. Age 18-75 years, regardless of gender.\n   3. ECOG performance status 0-2.\n   4. Life expectancy ≥6 months.\n   5. Good organ function:\n\n      • Hematological: Neutrophils ≥1.5×10⁹\u002FL, hemoglobin ≥9 g\u002FdL, platelets ≥100×10⁹\u002FL.\n\n      • Liver function: Bilirubin ≤1.5×ULN (patients with known Gilbert disease and serum bilirubin ≤3×ULN are eligible); AST and ALT ≤2.5×ULN (if liver metastasis is present, AST and ALT ≤5×ULN); alkaline phosphatase ≤3×ULN (if liver or bone metastasis is present, ALP ≤5×ULN); albumin ≥3 g\u002FdL.\n      * Coagulation function: International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (aPTT) ≤1.5×ULN.\n      * Renal function: Creatinine clearance rate ≥60 mL\u002Fmin (calculated by Cockcroft-Gault formula).\n      * Urine protein ≤1+ or 24-hour urine protein \\\u003C1.0 g.\n      * Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%.\n   6. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first drug administration (if the urine test is inconclusive, a serum test is required, with the serum result as the standard). If a female patient of childbearing potential has sexual activity with an unsterilized male partner, she must use an acceptable contraceptive method from screening and agree to continue contraception for 120 days after the last administration of the study drug. Whether to discontinue contraception after this period should be discussed with the investigator. Male patients who are not sterilized and have sexual activity with female partners of childbearing potential must use effective contraception from screening to 120 days after the last administration. Whether to discontinue contraception after this period should be discussed with the investigator.\n\nExclusion Criteria:\n\n* (1) Cancer-specific exclusion criteria:\n\n  a) Active or untreated CNS metastases (e.g., brain or leptomeningeal metastases) confirmed by CT or magnetic resonance (MRI) evaluation during screening and prior imaging. Patients who have received treatment for brain or leptomeningeal metastases, have been stable for ≥2 months, and have discontinued systemic hormonal therapy (\\>10 mg\u002Fd prednisone or equivalent) \\>4 weeks before randomization may participate.\n\n  b) Uncontrolled tumor-related pain. c) Thromboembolic disease, ascites, or lower limb edema within the past 6 months.\n\n  d) History of malignant tumors other than lung cancer within 5 years before randomization, except for malignancies with negligible risk of metastasis or death \\[e.g., expected 5-year overall survival rate \\>90%\\] and expected to be cured after treatment, such as appropriately treated cervical in situ carcinoma, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery.\n\n  e) Unresolved toxicity from prior antitumor therapy, defined as failure to recover to NCI CTCAE v5.0 grade 0 or 1 (except alopecia) or to the levels specified in the inclusion\u002Fexclusion criteria.\n\n  (2) General medical exclusion criteria:\n  1. Women who are pregnant, lactating, or planning to become pregnant during the study.\n  2. Patients with hepatitis B (known HBsAg-positive and HBV DNA ≥1000 cps\u002Fml or 200 IU\u002Fml or ≥ the upper limit of normal at each study center) or hepatitis C:\n\n     ● For patients with a history of HBV infection, HBV DNA testing must be performed, and they are eligible only if HBV DNA is negative (HBV DNA \\\u003C1000 cps\u002Fml or 200 IU\u002Fml or below the upper limit of normal).\n     * Among patients with positive HCV antibody, only those with negative HCV RNA by polymerase chain reaction (PCR) may participate.\n  3. Patients with positive human immunodeficiency virus (HIV) test results.\n  4. Receipt of major surgery (excluding diagnostic surgery) within 28 days before randomization, or expected to undergo major surgery during the study.\n  5. Significant cardiovascular diseases, such as heart disease defined by the New York Heart Association (class II or higher), myocardial infarction within 3 months before randomization, unstable arrhythmia, unstable angina, cerebrovascular accident, or transient ischemic attack. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\\u003C50% must receive the optimal stable treatment regimen as determined by their attending physician, with consultation from a cardiologist if necessary.\n  6. Severe infection within 4 weeks before the first drug administration, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks before the first drug administration (excluding antiviral therapy for hepatitis B or C).\n\n     (3) Medication-related exclusion criteria:\n\n  \u003C!-- -->\n\n  1. Any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, uncontrollable vomiting; patients with difficulty in food intake or requiring enteral or parenteral nutrition support; anorexia nervosa, anorexia due to mental illness, or difficulty in eating due to pain.\n  2. Current or planned use of other appetite or weight-increasing medications, such as adrenal corticosteroids (except short-term dexamethasone use during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n  3. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; poorly controlled diabetes; current hypertension with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite oral antihypertensive treatment.\n  4. History of esophageal-gastric varices, severe ulcers, gastrointestinal perforation and\u002For fistula, gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first drug administration.\n  5. Known allergy to any component of the study drug.\n  6. Other circumstances deemed unsuitable by the investigator.",{"count":109,"type":20},116,[23],"Patients with advanced lung cancer are a high-risk population for cancer-related anorexia-cachexia syndrome (CACS). Meanwhile, the adverse reactions of chemotherapy and immunotherapy potentially exacerbate the occurrence and progression of CACS. CACS seriously affects the quality of life of patients with advanced lung cancer, significantly shortens the overall survival (OS) and progression-free survival (PFS), forming a vicious cycle. A number of previous studies have shown that combined supportive therapies such as megestrol acetate during chemotherapy or concurrent chemoradiotherapy for advanced tumor patients is a clinically meaningful and feasible treatment model in clinical practice. However, the efficacy and optimal treatment timing of combination with current first-line immunochemotherapy regimens remain unclear. Although mechanistic studies have shown that anti-cachexia therapy may synergistically enhance the efficacy of immunotherapy, relevant clinical research evidence is lacking.\n\nTherefore, this study hypothesizes that the combination of first-line immunochemotherapy regimen and nano-crystalline megestrol acetate can improve the clinical benefits of patients with advanced lung cancer. It is planned to enroll patients with advanced lung cancer who present with anorexia-cachexia, and administer nano-crystalline megestrol acetate intervention (nano-crystalline megestrol acetate or its placebo control) during first-line immunochemotherapy. The changes in body weight relative to the baseline, as well as the impact on survival benefits and quality of life of patients, will be detected. In China, megestrol acetate is mainly available in two dosage forms: oral suspension and dispersible tablets. The oral suspension of megestrol acetate adopts nano-crystal technology (referred to as nano-crystalline megestrol acetate), which reduces the particle size of megestrol acetate and improves bioavailability. Previous randomized controlled studies have shown that it is superior to non-nano-crystal dosage forms in improving body weight.",[113,114],"Lung Cancer","Cachexia-Anorexia Syndrome","2025-07-27",{"date":117,"type":31},"2025-07-29",{"date":119,"type":20},"2025-10-10",{"date":121,"type":20},"2027-10-10",{"name":37,"class":38},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100585977","phase-2-nanocrystalline-megestrol-acetate-for-the-treatment-of-anorexia-cachexia-syndrome-in-extensive-stage-small-cell-lung-cancer-a-prospective-open-label-single-arm-phase-ii-clinical-study-100585977","NCT06909383","Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study","Inclusion Criteria:\n\nPatients who have been confirmed by histological or cytological examination to have small cell lung cancer (SCLC), and who have been identified as having extensive-stage small cell lung cancer based on the 8th edition of the AJCC staging system or the Veterans Administration Lung Group (VALG) criteria (excluding patients with combined small cell lung cancer).\n\nThe subjects have not received systemic chemotherapy for metastatic diseases in the past. For subjects who have previously received adjuvant\u002Fneoadjuvant chemotherapy aimed at cure for non-metastatic diseases, or radical concurrent or sequential chemoradiotherapy, if the disease progression occurs more than 6 months after the end of the last treatment, they are eligible to participate in this study.\n\nAccording to RECIST v1.1, there is at least one measurable tumor lesion. Meet the diagnostic criteria for the pre-cachexia or cachexia stage. -\n\nExclusion Criteria:\n\n1. Cancer-specific exclusion criteria:\n\n   1. Active or untreated CNS metastases (e.g., brain or leptomeningeal metastases) determined by CT or magnetic resonance imaging (MRI) evaluation during screening and previous imaging evaluations. Patients who have previously received treatment for brain or leptomeningeal metastases, have been stable for ≥ 2 months, and have discontinued systemic hormonal therapy (\\> 10 mg\u002Fday of prednisone or equivalent) for \\> 4 weeks before randomization may participate in the study.\n   2. Uncontrolled tumor-related pain;\n   3. Thromboembolic disease, ascites, or lower extremity edema within the past 6 months;\n   4. A history of malignant tumors other than lung cancer within 5 years before random assignment, except for malignant tumors with a negligible risk of metastasis or death \\[e.g., with an expected 5-year overall survival rate \\> 90%\\] and those expected to be cured after treatment, such as appropriately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery;\n   5. Persistent toxicity from previous anti-tumor treatment that has not been resolved. \"Not resolved\" is defined as not having recovered to grade 0 or 1 according to NCI CTCAE version 5.0 (excluding alopecia) or not having recovered to the level specified in the inclusion\u002Fexclusion criteria.\n2. General medical exclusion criteria:\n\n   1. Women who are pregnant, lactating, or planning to become pregnant during the study period;\n   2. Patients with hepatitis B (known to be positive for HBV surface antigen HBsAg and with HBV DNA detected at each study center ≥ 1000 cps\u002Fml or 200 IU\u002Fml or ≥ the upper limit of the normal value) or hepatitis C:\n\n      * For patients with a previous history of hepatitis B virus (HBV) infection, HBV deoxyribonucleic acid (DNA) testing must be performed on this group of patients. Only those with a negative HBV DNA result (HBV DNA \\\u003C 1000 cps\u002Fml or 200 IU\u002Fml or below the upper limit of the normal value) are eligible to participate in this study;\n      * Among patients with a positive hepatitis C virus (HCV) antibody, only those with a negative polymerase chain reaction (PCR) HCV ribonucleic acid (RNA) result can participate in this study.\n   3. Patients with a positive test result for human immunodeficiency virus (HIV);\n   4. Those who have undergone major surgery (excluding diagnostic surgery) within 28 days before random assignment, or are expected to undergo major surgery during the study period;\n   5. Significant cardiovascular diseases, such as heart diseases defined by the New York Heart Association (Class II or higher), myocardial infarction occurred within 3 months before random assignment, unstable arrhythmia, unstable angina pectoris, cerebrovascular accident or transient ischemic attack; Patients known to have coronary artery disease, congestive heart failure that does not meet the above criteria, or with a left ventricular ejection fraction \\\u003C 50% must receive the optimal stable treatment regimen considered by the attending physician, and consultation with a cardiologist is advisable if necessary;\n   6. Severe infections occurred within 4 weeks before the first administration, including but not limited to those with comorbidities requiring hospitalization, sepsis, or severe pneumonia; Active infections (excluding antiviral treatment for hepatitis B or hepatitis C) for which systemic anti-infective treatment was received within 2 weeks before the first administration.\n3. Exclusion criteria related to drug use:\n\n   1. Any condition that affects gastrointestinal absorption, such as dysphagia, malabsorption, uncontrollable vomiting, etc.; Patients with difficulty in food intake or those who require enteral or parenteral nutritional support; Patients with anorexia nervosa, anorexia caused by mental illness, or difficulty in eating due to pain.\n   2. Currently taking or planning to take other drugs that increase appetite or body weight, such as adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n   3. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; Patients with poorly controlled diabetes; Patients with current hypertension whose systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after treatment with oral antihypertensive drugs.\n   4. A history of esophageal-gastric varices, severe ulcers, gastrointestinal perforation and\u002For fistula, a history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first administration.\n   5. Known allergy to any component of the study drug.\n   6. Other situations that the investigator deems unsuitable.\n\n      \\-",{"count":130,"type":20},41,[23],"Patients with extensive-stage small cell lung cancer are a high-risk group for cancer cachexia and anorexia. Meanwhile, the adverse reactions of chemotherapy and immunotherapy potentially exacerbate the occurrence and development of cancer cachexia and anorexia. Cancer cachexia and anorexia also severely affect the quality of life of patients with extensive-stage small cell lung cancer, significantly shortening their overall survival (OS) and progression-free survival (PFS), thus forming a vicious cycle.\n\nNumerous previous studies have shown that for patients with advanced tumors, the combination of supportive treatments such as megestrol acetate during chemotherapy or concurrent chemoradiotherapy is a treatment mode with clinical significance and practical feasibility in clinical practice. However, the efficacy and the optimal treatment timing of its combination with the current first-line immunochemotherapy regimen remain unclear. Although mechanistic studies have shown that anti-cachexia treatment may synergistically enhance the efficacy of immunotherapy, there is a lack of relevant clinical research evidence.",[134,135],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Cancer - Associated Anorexia - Cachexia Syndrome","2025-03-27",{"date":138,"type":31},"2025-04-03",{"date":140,"type":20},"2025-06-01",{"date":142,"type":20},"2026-12-31",{"name":37,"class":38},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":157,"studyType":49,"phases":4,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":39},"100580701","association-between-genetic-polymorphisms-and-type-2-asthma-in-children-100580701","NCT06840717","Association Between Genetic Polymorphisms and Type 2 Asthma in Children","Association Between Cytokines Gene Single Nucleotide Polymorphisms and Type 2 Inflammatory Asthma in Children","SNP","Inclusion Criteria:\n\n1. All children with asthma diagnosis accord with the GINA in 2023 edition;\n2. Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies;\n3. In front of the hospital 2 weeks without antibiotics, systemic hormone medication history;\n4. There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc.\n\nExclusion Criteria:\n\n1. Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission;\n2. Children with primary immunodeficiency disease;\n3. The children and their families failed to cooperate or refused the experimental observation.",true,"3 Years","14 Years",{"count":156,"type":20},300,"1 Year","To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.",[160,161,162],"Asthma in Children","Genetic Disease","Inflammation",[164,165,166,167,168],"cytokines","Single nucleotide polymorphism","type 2 inflammation","ashtma","Susceptibility","2025-02-18",{"date":171,"type":31},"2025-02-21",{"date":173,"type":31},"2024-01-30",{"date":175,"type":20},"2025-12-30",{"name":37,"class":38},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":39},"100575451","to-evaluate-the-efficacy-and-safety-of-inhaled-corticosteroids-combined-with-bronchodilators-and-programmed-death-ligand-1-pd-l1-inhibitor-plus-platinum-based-chemotherapy-in-patients-with-advanced-lung-squamous-cell-carcinoma-complicated-with-chronic-obstructive-pulmonary-disease-copd-100575451","NCT06772454","To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* This project is a multi-center, randomized controlled, intentionality analysis study.\n\nInclusion criteria:\n\n1. Age ≥18 years old;\n2. Histological or cytological examination confirmed clinically primary squamous non-small cell lung cancer stage IIIB-IV (according to AJCC 8th Edition);\n3. Patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) were diagnosed according to the GOLD2021 standard and the Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (Revised 2021), with blood eosinophils ≤300 \u002Ful and ≥100 \u002Ful;\n4. The gene test showed that the driver gene (EGFR\u002FALK\u002FBRAF\u002FROS1\u002FKRAS\u002F HER2\u002FMET\u002FRET \u002FNTRK) was negative;\n5. ECOG PS 0-2 points;\n6. Clinical evaluation is suitable for suglizumab combined with paclitaxel (albumin-bound) and carboplatin anti-tumor first-line therapy, as well as chronic obstructive pulmonary maintenance therapy with long-acting bronchodilators or inhaled corticosteroids;\n7. Clinical records of suglizumab treatment, chemotherapy and other treatments are available;\n8. Patients who have previously used bronchodilators and inhaled corticosteroids should undergo a washout period of at least 15 days;\n9. Patients voluntarily join the project and sign informed consent;\n\nExclusion Criteria:\n\n* 10\\. Concurrent with any malignant active tumor other than squamous non-small cell lung cancer; 11. Prior systematic treatment for advanced\u002Fmetastatic non-small cell lung cancer; 12. Patients with diseases requiring long-term oral or intravenous use of glucocorticoids, such as autoimmune diseases, asthma, nephritis, type 1 diabetes, hyperthyroidism, etc.; Etc.; 13. Oral or intravenous use of glucocorticoids for any reason within 1 month prior to screening; 14. The patient was assessed by the researchers as having severe liver and kidney dysfunction; 15. Accompanied by acute type I\u002FII respiratory failure or long-term use of non-invasive or invasive ventilator assisted ventilation or frequent acute exacerbations (≥2 times\u002Fyear of moderate and severe acute exacerbations); 16. Women who are pregnant or nursing, or who are planning to become pregnant; Currently receiving or planning to participate in any other clinical studies;",{"count":74,"type":20},"To evaluate the efficacy and safety of inhaled corticosteroids combined with bronchodilators and programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy in patients with advanced lung squamous cell carcinoma complicated with chronic obstructive pulmonary disease (COPD)",[186,187],"Lung Cancer Squamous Cell","COPD","2025-01-08",{"date":190,"type":31},"2025-01-13",{"date":192,"type":31},"2023-01-01",{"date":194,"type":20},"2025-12-12",{"name":37,"class":38},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":39},"100572950","phase-2-irinotecan-liposome-ii-or-etoposide-combined-with-adebrelimab-and-carboplatin-in-the-treatment-of-es-sclc-100572950","NCT06739928","Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC","A Safety and Efficacy Evaluation Study of Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC","Inclusion Criteria:\n\n* Pathologically confirmed small cell lung cancer (SCLC), staged as extensive-stage SCLC (ES-SCLC) according to the VALG staging system;\n* No prior systemic treatment received;\n* At least a 6-month interval between the last treatment (radiation therapy and chemotherapy) and diagnosis of extensive-stage SCLC;\n* Showing at least one target lesion (RECIST 1.1) that has not been previously irradiated;\n* Male or female patients aged ≥18 and ≤70 years;\n* ECOG performance status (PS) score of 0 or 1;\n* Life expectancy of ≥12 weeks;\n* Adequate organ function: (1) Hematologic: WBC ≥ 3.0 × 10⁹\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, HGB ≥ 9.0 g\u002FdL.(2) Hepatic function: AST ≤ 2.5 × ULN, ALT ≤ 2.5 × ULN, liver metastases allowed if ALT and AST ≤ 5 × ULN, TBIL ≤ 1.5 × ULN (except for Gilbert's syndrome, where total bilirubin ≤ 3.0 mg\u002FdL),(3) Renal function: Cr ≤ 1.5 × ULN or CrCl ≥ 50 mL\u002Fmin, (4) Coagulation: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN;\n* Agreement to use an appropriate contraceptive method from the first dose of the study treatment until 6 months after the last dose of the study treatment. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment;\n* The patient must have fully understood the study and voluntarily consent to participate by signing the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Histologically or cytologically confirmed mixed small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC);\n* Previous treatment with immune checkpoint inhibitors, or treatment with irinotecan or other DNA topoisomerase inhibitors;\n* Use of a strong CYP3A4 inducer within 2 weeks prior to the first dose of the investigational drug, or a strong CYP3A4 inhibitor or UGT1A1 inhibitor within 1 week prior to the first dose;\n* Presence of clinically symptomatic brain metastasis, leptomeningeal metastasis, or spinal cord compression;\n* Hematologic disorders, including but not limited to lymphoma, acute or chronic leukemia, multiple myeloma, aplastic anemia, myelodysplastic syndrome, etc;\n* Clinically symptomatic third-space fluid accumulation, such as pericardial effusion, pleural effusion, or ascites that cannot be controlled by drainage or other treatments;\n* Active, known, or suspected autoimmune disease;\n* Use of corticosteroids (doses\\> 10 mg\u002Fday of prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of the study drug;\n* Receipt of live vaccines or planned vaccination with a live vaccine within 4 weeks prior to the first dose of the study drug;\n* Interstitial lung disease, drug-induced pneumonia, radiation-induced pneumonia requiring steroid treatment, or clinically symptomatic active pneumonia, or severe pulmonary dysfunction;\n* Active tuberculosis or a history of active tuberculosis within 48 weeks prior to screening, regardless of whether it was treated;\n* Any toxicity from previous anticancer therapy, that has not resolved to grade ≤1 (according to CTCAE v5.0) prior to the first dose of the investigational drug;\n* Underwent a minor surgery (including catheter placement) within 48 hours prior to the first dose of the study drug;\n* Presence of uncontrolled cardiovascular symptoms or diseases;\n* Hypersensitivity to the investigational drug or its excipients;\n* A history of any other malignancy within 5 years prior to the first dose of the study drug, except for adequately treated non-melanoma skin cancer or in situ carcinoma;\n* A history of psychiatric disorders, alcohol abuse, drug abuse, or substance misuse;\n* HBsAg-positive and HBV DNA levels exceeding the upper limit of normal, or HCV-positive (HCV RNA or HCV Ab indicating acute or chronic infection); a history of HIV-positive status or acquired immunodeficiency syndrome (AIDS);\n* Received any other investigational drug or participated in another interventional clinical trial within 4 weeks prior to signing the informed consent form (ICF);\n* A history of allogeneic bone marrow transplantation or solid organ transplantation;\n* Any other factors as determined by the investigator.","70 Years",{"count":205,"type":20},120,[23],"This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.",[209],"Small Cell Lung Cancer Extensive Stage",[211,212,213,214,215],"ES-SCLC","extensive stage-small cell lung cancer","adebrelimab","Irinotecan liposome (II)","zhou chengzhi","2024-12-13",{"date":218,"type":31},"2024-12-18",{"date":220,"type":20},"2025-01-01",{"date":222,"type":20},"2027-12-30",{"name":37,"class":38},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":233,"studyType":49,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":243,"locationsCount":39},"100571108","observational-study-of-sputum-inflammation-phenotypes-and-clinical-outcomes-in-non-cystic-fibrosis-bronchiectasis-100571108","NCT06715956","Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis","A Multicenter, Observational Study to Investigate Sputum Inflammation Phenotyping and Predict Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis, with Subsequent Participation in the HSK31858 Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years and BMI≥18.0 kg\u002Fm\\^2 at the time of signing the ICF.\n2. Chest HRCT showed bronchiectasis affecting one or more lobes and was confirmed by a clinician as NCFBE(clinically characterized by chronic cough, expectoration and\u002For intermittent hemoptysis, with or without shortness of breath and respiratory failure). HRCT was considered effective if the patient had received HRCT in the same hospital within 12 months and screening HRCT is not necessary.\n3. Have at least 2 pulmonary exacerbations in the past 12 months before Screening.\n4. If long-term treatment with bronchodilators (long-acting β-agonists and\u002For long-acting muscarinic antagonists) is required, the dose and regimen should remain stable for at least 3 months before the screening visit and throughout the study period.\n5. The estimated survival time ≥ 12 months.\n6. Women must be post-menopausal, surgically sterile, or using highly effective contraception methods from Day 1 to at least 30 days after the last dose.\n7. Males with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose.\n8. Give their signed study informed consent to participate.\n\nExclusion Criteria:\n\n1\\. Have a primary diagnosis of COPD or asthma as judged by the Investigator. 2. A history of malignancy (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary carcinoma of the thyroid gland. The patients who had survived lung cancer surgery for at least 5 years without antitumor therapy can enroll in the study ) within 5 years prior to screening or a history of antitumor therapy.\n\n3\\. Have bronchiectasis due to CF (HRCT showed that the above lung diseases became predominant) as judged by the Investigator.\n\n4\\. Currently being treated Non-tuberculous Mycobacterial (NTM) pulmonary infections, allergic bronchopulmonary aspergillosis, or tuberculosis (TB), or active and currently symptomatic infections caused by COVID-19, or have the history of bronchopulmonary aspergillosis.\n\n5\\. Patients with severe pulmonary fibrosis such as lung destruction, pneumonectomy surgery history, and pneumoconiosis, as well as previous or existing decompensated stage of pulmonary heart disease.\n\n6\\. Patients who had experienced any degree of acute exacerbation of bronchiectasis or were developing an acute exacerbation of bronchiectasis before 4 weeks of screening.\n\n7\\. Patients who had hemoptysis and required medical intervention within 4 weeks prior to screening(except for coughing up minorbloody streaks).\n\n8\\. Patients previously treated with HSK31858 or other DPP1 inhibitor products. 9. Subjects with uncontrolled hypertension (SBP ≥180 mmHg at rest and\u002For DBP ≥110 mmHg).\n\n10\\. Subjects with uncontrolled type 1 or type 2 diabetes (fasting plasma glucose \\>7.0 mmol\u002FL).\n\n11\\. Subjects with a history of liver disease or current treatment for liver disease during the screening period, including but not limited to acute or chronic hepatitis, cirrhosis or liver failure (except for mild to moderate non-alcoholic fatty liver disease).\n\n12\\. Active hepatitis B virus infection (hepatitis B surface antigen positive with HBV-DNA load above the lower limit of detection), active hepatitis C virus infection (HCV antibody positive with HCV-RNA load above the lower limit of detection), or known HIV infection or syphilis infection.\n\n13\\. Any other unstable clinical condition, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or major physiological dysfunction, that the investigator considers to be (a) likely to affect patient safety throughout the study; (b) Influence the results of the study and its interpretation; (c) impeding the patient\\'s ability to complete the entire study.\n\n14\\. Laboratory tests during the screening period meet the following conditions: AST\\>2.0×ULN or ALT\\>2.0×ULN or TBIL\\>1.5×ULN eGFR\\<60ml\u002Fmin\u002F1.73m2 Hb\\\u003C90 g\u002FL WBC \\\u003C3×109 \u002FL PLT \\\u003C70×109 \u002FL INR\\>1.5ULN，PT\\>ULN+3s, or APTT\\>ULN+10s. 15. Had participated in a clinical trial of any other drug or medical device in the 3 months prior to the screening (a drug or medical device treated with a clinical trial) or the subject had not been more than 5 half-lives from the last clinical trial of the drug at the time of screening.\n\n16\\. Medications that may cause hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening.\n\n17\\. Patients who have used a strong inducer or suppressor of CYP3A within 14 days or 5 half-lives of the first investigational drug (whichever is longer).\n\n18\\. Patients who had smoked an average of 10 cigarettes or more per day in the previous 1 year were screened.\n\n19\\. Pregnancy and lactation. 20. The subjects were unable to complete the questionnaires due to their limited educational level, or the subjects and their families failed to fill in the subjects\\' log cards.\n\n21\\. Had received live attenuated vaccine within 30 days before randomization. 22. The investigators judged that there were other conditions that were not suitable for participation in the study.",{"count":232,"type":20},400,"52 Weeks","This is an observational, multicenter study aimed at investigating the inflammation phenotypes in sputum samples from patients with non-cystic fibrosis bronchiectasis (NCFBE). The study will observe and classify these phenotypes during the clinical screening phase without any intervention. Patients enrolled in this study may later participate in the HSK31858 clinical trial, where they will receive treatment as part of the trial protocol. After the unblinding of the trial, the study will analyze the relationship between sputum inflammation phenotypes and clinical outcomes, including treatment response and prognosis. The goal is to develop a clinical prediction model that incorporates inflammation subtypes to better predict patient outcomes in bronchiectasis.",[236],"Non-cystic Fibrosis Bronchiectasis (NCFBE)","2024-11-28",{"date":239,"type":31},"2024-12-04",{"date":33,"type":20},{"date":242,"type":20},"2027-01-01",{"name":37,"class":38},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":4},"100563738","causal-relationship-between-plasma-vegf-family-proteins-and-placenta-previa-a-two-sample-mendelian-randomization-study-100563738","NCT06620068","Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study","Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study","VEGF PP","Inclusion Criteria:\n\n* Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.\n\nExclusion Criteria:\n\n* Participants with incomplete or missing data on plasma VEGF levels or placenta previa.",{"count":253,"type":20},207473,"This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.",[256],"Placenta Previa",[258,259,260,261,262],"Vascular Endothelial Growth Factor (VEGF)","Mendelian Randomization","Angiogenesis","Pregnancy Complications","Placental Development","2024-09-26",{"date":265,"type":31},"2024-10-01",{"date":267,"type":20},"2024-09-25",{"date":33,"type":20},{"name":37,"class":38},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":4},"100497598","an-exploratory-study-of-ctdna-mrd-in-predicting-the-efficacy-of-esophageal-squamous-cell-carcinoma-100497598","NCT05759325","An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma","Application of ctDNA-MRD in the Prediction of Curative Effect, Recurrence Monitoring and Prognosis Evaluation of Esophageal Squamous Cell Carcinoma (ESCC) During Perioperative Treatment","Inclusion Criteria:\n\n1. Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging;\n2. ≥18 years;\n3. Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0 \\~ 1 points;\n4. Expected survival time ≥ 6 months;\n5. Patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps.\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors;\n2. Patient had undergone surgery before admission;\n3. Pregnant or lactating women;\n4. Patients with other serious diseases;\n5. Patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form;\n6. Patients with contraindications to radiotherapy and chemotherapy;\n7. Other researchers think it is not suitable.","80 Years",{"count":279,"type":20},100,"The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.",[282],"Squamous Cell Carcinoma of Esophagus",[284,285],"ESCC","ctDNA","2023-02-25",{"date":288,"type":31},"2023-03-08",{"date":290,"type":20},"2023-03",{"date":35,"type":20},{"name":37,"class":38},""]